Ph II Early BC Pre-Surgical Biologic Study

• Status: Completed
• Trial end date: 2005-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

A pre-surgery study to assess changes that occur in human breast cancer material and normal skin after a short course of treatment with Iressa.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Cancer International Research Group (CIRG)
• Treatments: Gefitinib

Criteria

Inclusion Criteria:

• Invasive breast cancer, Aged 18 years or older, Not more than 28 days from initial diagnosis

Exclusion Criteria:

• Pregnant or lactating patients, Prior or current radiotherapy for breast cancer, Known allergy reaction to Iressa